Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 11/2018

01-11-2018 | Original Article

A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptoms

Authors: Mohamed Tharwat, Mohamed M. Elsaadany, Ahmed M. Lashin, Ahmed R. EL-Nahas

Published in: World Journal of Urology | Issue 11/2018

Login to get access

Abstract

Purpose

To evaluate the role of sildenafil in relieving ureteral stent symptoms.

Patients and methods

A randomized controlled trial was conducted between March 2014 and November 2016. It included adult men who underwent unilateral ureteric stent after ureteroscopy. Patients who were taking PDE5-Is, alpha-blockers or anticholinergics, had contraindication to sildenafil or developed postoperative complications were not included. Eligible patients were randomized using sealed closed envelops to one of two groups (S and C). Patients in group S received sildenafil citrate 50 mg tablet once daily. Patients in group C were the control. All patients answered the ureteral stent symptom questionnaire (USSQ) after 2 weeks of stenting. Primary outcome was the difference in total USSQ score between both groups. Secondary outcomes were tolerability of the treatment and the difference in each domain of USSQ score.

Results

After randomization, four patients (7.3%) in group C withdraw their consent because of severe symptoms and two patients (3.6%) in group S discontinued treatment because of headache and dizziness. Final analysis was performed for 46 and 48 patients in groups C and S, respectively. Total USSQ score and all domains (except work performance) were significantly lower in group S (P < 0.001). Dysuria and urgency were significantly more in group C (P = 0.012 and 0.007, respectively). Three patients in groups S (6.25%) experienced transient mild adverse effects (dyspepsia, flushing and rhinitis in one patient for each) but they continued sildenafil.

Conclusions

Sildenafil is an effective and well-tolerated treatment option for relieving ureteral stent-related symptoms in men.

ClinicalTrial.gov Identifier

NCT02345980.
Literature
1.
Scameciu I, Lupu S, Pricop C, Morbidity SC (2015) Impact on quality of life in patients with indwelling ureteral stents: a 10-year clinical experience. Pak J Med Sci 31:522–526
2.
El-nahas A, El-assmy A, Shoma A, Eraky I, El-kenawy M, El-kappany H (2006) Self-retaining ureteral stents: analysis of factors responsible for patients’ discomfort. J Endourol 20:33–37CrossRef
3.
Lingeman JE, Preminger GM, Goldfischer ER, Krambeck AE (2009) Assessing the impact of ureteral stent design on patient comfort. J Urol 181:2581–2587CrossRef
4.
Dellis A, Joshi HB, Timoney AG, Keeley FX Jr (2010) Relief of stent related symptoms: review of engineering and pharmacological solutions. J Urol 184:1267–1272CrossRef
5.
Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ (2011) Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort. BJU Int 108:1894–1902CrossRef
6.
Zhou L, Cai X, Li H, Wang KJ (2015) Effects of α-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol 29:650–656CrossRef
7.
Koprowski C, Kim C, Modi PK, Elsamra SE (2016) Ureteral stent-associated pain: a review. J Endourol 30:744–753CrossRef
8.
Gacci M, Corona G, Salvi M et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003CrossRef
9.
Zhang LT, Park JK (2015) Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia? World J Nephrol 4:138–147CrossRef
10.
Oger S, Behr-Roussel D, Gorny D et al (2010) Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol 160:1135–1143CrossRef
11.
Gacci M, del Popolo G, Macchiarella A, Celso M et al (2007) Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 178:2040–2043CrossRef
12.
Shokeir AA, Tharwat MA, Abolazm AE, Harraz A (2016) Sildenafil citrate as a medical expulsive therapy for distal ureteric stones: a randomised double-blind placebo-controlled study. Arab J Urol. 14:1–6CrossRef
13.
Aggarwal SP, Priyadarshi S, Tomar V (2015) A randomized controlled trial to compare the safety and efficacy of tadalafil and tamsulosin in relieving double J stent related symptoms. Adv Urol 2015:592175CrossRef
14.
El-Nahas AR, El-saadony MM, Tharwat M et al (2014) Validation of Arabic linguistic version of ureteral stent symptoms questionnaire. Arab J Urol 12:290–293CrossRef
15.
Mendez-Probst CE, Goneau LW, MacDonald KW et al (2012) The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial.”. BJU Int 110:749–754CrossRef
16.
Krambeck AE, Walsh RS, Denstedt JD et al (2010) A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol 183:1037–1042CrossRef
17.
McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071–1077CrossRef
18.
Fibbi B, Morelli A, Vignozzi L et al (2010) Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 7:59–69CrossRef
19.
Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L (2013) The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 63:506–516CrossRef
20.
Gratzke C, Ückert S, Kedia G et al (2007) In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res 35:49–54CrossRef
Metadata
Title
A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptoms
Authors
Mohamed Tharwat
Mohamed M. Elsaadany
Ahmed M. Lashin
Ahmed R. EL-Nahas
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 11/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2339-y

Other articles of this Issue 11/2018

World Journal of Urology 11/2018 Go to the issue

Letter to the Editor

Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma

Original Article

Laparoscopic single-incision triangulated umbilical surgery (SITUS) pyeloplasty: a description of the first 32 cases

Original Article

Surgical margin status and its impact on prostate cancer prognosis after radical prostatectomy: a meta-analysis

Original Article

Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy

Original Article

Outcome of flexible ureteroscopy for renal stone with overnight ureteral catheterization: a propensity score-matching analysis

Topic Paper

Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era